Patent · US Active

Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene

US7846907B2 · kind B2 · utility

5Cited by

4References

8Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Olaf Heidenreich · Bingen, DE
Hans-Peter Vornlocher · Bayreuth, DE
Roland Kreutzer · Weidenberg, DE
Stefan Limmer · Neudrossenfeld, DE

Key dates

Filing date	Jan 22, 2007
Grant date	Dec 7, 2010
Priority date	—
Expiry date	Jan 22, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/53
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19-24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.